Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Cost-effectiveness of second-line diagnostic investigations in patients included in the DANTE trial: a randomized controlled trial of lung cancer screening with low-dose computed tomography.

Lopci E, Castello A, Morenghi E, Tanzi D, Cavuto S, Lutman F, Chiesa G, Vanni E, Alloisio M, Infante M.

Nucl Med Commun. 2019 May;40(5):508-516. doi: 10.1097/MNM.0000000000000993.

PMID:
30875336
2.

Early Catheter Removal After Robot-assisted Radical Prostatectomy: Results from a Prospective Single-institutional Randomized Trial (Ripreca Study).

Lista G, Lughezzani G, Buffi NM, Saita A, Vanni E, Hurle R, Cardone P, Peschechera R, Forni G, Lazzeri M, Guazzoni G, Casale P.

Eur Urol Focus. 2018 Nov 6. pii: S2405-4569(18)30314-6. doi: 10.1016/j.euf.2018.10.013. [Epub ahead of print]

PMID:
30413390
3.

Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease.

Manfredi M, Conte E, Barberis E, Buzzi A, Robotti E, Caneparo V, Cecconi D, Brandi J, Vanni E, Finocchiaro M, Astegiano M, Gariglio M, Marengo E, De Andrea M.

J Proteomics. 2019 Mar 20;195:138-149. doi: 10.1016/j.jprot.2018.10.017. Epub 2018 Nov 2.

4.

Cost analysis and outcome of endoscopic submucosal dissection for colorectal lesions in an outpatient setting.

Maselli R, Galtieri PA, Di Leo M, Ferrara EC, Anderloni A, Carrara S, Vanni E, Mangiavillano B, Genco A, Al Awadhi S, Fuccio L, Hassan C, Repici A.

Dig Liver Dis. 2019 Mar;51(3):391-396. doi: 10.1016/j.dld.2018.09.023. Epub 2018 Oct 12.

PMID:
30385079
5.

Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute.

Novellis P, Bottoni E, Voulaz E, Cariboni U, Testori A, Bertolaccini L, Giordano L, Dieci E, Granato L, Vanni E, Montorsi M, Alloisio M, Veronesi G.

J Thorac Dis. 2018 Feb;10(2):790-798. doi: 10.21037/jtd.2018.01.123.

6.

Risk factors for arterial hypertension after liver transplantation.

Di Stefano C, Vanni E, Mirabella S, Younes R, Boano V, Mosso E, Nada E, Milazzo V, Maule S, Romagnoli R, Salizzoni M, Veglio F, Milan A.

J Am Soc Hypertens. 2018 Mar;12(3):220-229. doi: 10.1016/j.jash.2018.01.002. Epub 2018 Jan 5.

PMID:
29366595
7.

Personality biomarkers of pathological gambling: A machine learning study.

Cerasa A, Lofaro D, Cavedini P, Martino I, Bruni A, Sarica A, Mauro D, Merante G, Rossomanno I, Rizzuto M, Palmacci A, Aquino B, De Fazio P, Perna GR, Vanni E, Olivadese G, Conforti D, Arabia G, Quattrone A.

J Neurosci Methods. 2018 Jan 15;294:7-14. doi: 10.1016/j.jneumeth.2017.10.023. Epub 2017 Nov 1.

PMID:
29080669
8.

Robotic lung cancer surgery: review of experience and costs.

Novellis P, Alloisio M, Vanni E, Bottoni E, Cariboni U, Veronesi G.

J Vis Surg. 2017 Mar 31;3:39. doi: 10.21037/jovs.2017.03.05. eCollection 2017. Review.

9.

Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project.

Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, Saita A, Morenghi E, Forni G, Cardone P, Lista G, Colombo P, Peschechera R, Pasini L, Zandegiacomo S, Benetti A, Maffei D, Vavassori I, Guazzoni G.

J Urol. 2018 Feb;199(2):401-406. doi: 10.1016/j.juro.2017.08.091. Epub 2017 Aug 26.

PMID:
28847481
10.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

11.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

12.

Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?".

Vanni E, Bugianesi E, Saracco GM.

Dig Liver Dis. 2016 Sep;48(9):1101-2. doi: 10.1016/j.dld.2016.06.017. Epub 2016 Jun 28. No abstract available.

PMID:
27443491
13.

Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?

Vanni E, Bugianesi E, Saracco G.

Dig Liver Dis. 2016 Feb;48(2):105-11. doi: 10.1016/j.dld.2015.10.016. Epub 2015 Oct 27. Review.

14.

Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis.

Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, Olivero A, Marengo A, Rizzetto M, Bugianesi E, Smedile A.

Dig Liver Dis. 2016 Jan;48(1):55-61. doi: 10.1016/j.dld.2015.09.008. Epub 2015 Sep 28.

PMID:
26514735
15.

Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.

Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Younes R, Saponaro C, Buzzigoli E, Caviglia GP, Abate ML, Smedile A, Rizzetto M, Cassader M, Gastaldelli A, Bugianesi E.

Hepatology. 2016 Jan;63(1):107-16. doi: 10.1002/hep.28287. Epub 2015 Dec 8. Erratum in: Hepatology. 2017 Sep;66(3):1011.

PMID:
26473614
16.

Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.

Vanni E, Marengo A, Mezzabotta L, Bugianesi E.

Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17. Review.

PMID:
26378641
17.

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

Turola E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL, Bianchini M, Raos N, Bugianesi E, Mercorella S, Di Giovanni M, Craxì A, Fargion S, Grieco A, Cammà C, Cotelli F, Villa E.

Dis Model Mech. 2015 Sep;8(9):1037-46. doi: 10.1242/dmm.019950. Epub 2015 Jul 16.

18.

PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.

Petta S, Vanni E, Bugianesi E, Rosso C, Cabibi D, Cammà C, Di Marco V, Eslam M, Grimaudo S, Macaluso FS, McLeod D, Pipitone RM, Abate ML, Smedile A, George J, Craxì A.

Aliment Pharmacol Ther. 2015 May;41(10):939-48. doi: 10.1111/apt.13169. Epub 2015 Mar 20.

19.

Editorial: utility and pitfalls of Fatty Liver Index in epidemiologic studies for the diagnosis of NAFLD.

Vanni E, Bugianesi E.

Aliment Pharmacol Ther. 2015 Feb;41(4):406-7. doi: 10.1111/apt.13063. No abstract available.

20.

Response to Dr. Sertoglu and colleagues.

Petta S, Vanni E, Craxì A.

Liver Int. 2015 Jan;35(1):285-6. doi: 10.1111/liv.12653. Epub 2014 Aug 25. No abstract available.

PMID:
25131005
21.

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.

Petta S, Vanni E, Bugianesi E, Di Marco V, Cammà C, Cabibi D, Mezzabotta L, Craxì A.

Liver Int. 2015 May;35(5):1566-73. doi: 10.1111/liv.12584. Epub 2014 May 20.

22.

Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease.

Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, Liaquat H, Mezzabotta L, Lee E, Bugianesi E.

Clin Gastroenterol Hepatol. 2014 Jul;12(7):1163-1169.e1. doi: 10.1016/j.cgh.2013.11.035. Epub 2013 Dec 14.

23.

Obesity and liver cancer.

Vanni E, Bugianesi E.

Clin Liver Dis. 2014 Feb;18(1):191-203. doi: 10.1016/j.cld.2013.09.001. Epub 2013 Oct 24. Review.

PMID:
24274874
24.

Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation.

Cuchet-Lourenço D, Vanni E, Glass M, Orr A, Everett RD.

J Virol. 2012 Oct;86(20):11209-22. Epub 2012 Aug 8.

25.

Functional characterization of residues required for the herpes simplex virus 1 E3 ubiquitin ligase ICP0 to interact with the cellular E2 ubiquitin-conjugating enzyme UBE2D1 (UbcH5a).

Vanni E, Gatherer D, Tong L, Everett RD, Boutell C.

J Virol. 2012 Jun;86(11):6323-33. doi: 10.1128/JVI.07210-11. Epub 2012 Mar 21.

26.

A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence.

Boutell C, Cuchet-Lourenço D, Vanni E, Orr A, Glass M, McFarlane S, Everett RD.

PLoS Pathog. 2011 Sep;7(9):e1002245. doi: 10.1371/journal.ppat.1002245. Epub 2011 Sep 15.

27.

Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.

Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G, Fargion S.

J Hepatol. 2011 Jun;54(6):1244-9. doi: 10.1016/j.jhep.2010.09.037. Epub 2010 Nov 11.

28.

Practical out-patient management of autoimmune hepatitis.

Vanni E, Actis GC, Ciancio A, Pellicano R, Abate ML, Touscoz GA, Smedile A, Rizzetto M.

Panminerva Med. 2010 Sep;52(3):265. No abstract available.

PMID:
21045783
29.

Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study.

Valenti L, Moscatiello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G.

QJM. 2011 Feb;104(2):141-9. doi: 10.1093/qjmed/hcq170. Epub 2010 Sep 17.

PMID:
20851820
30.

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP.

Hepatology. 2010 Apr;51(4):1209-17. doi: 10.1002/hep.23622.

PMID:
20373368
31.

From the metabolic syndrome to NAFLD or vice versa?

Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.

Dig Liver Dis. 2010 May;42(5):320-30. doi: 10.1016/j.dld.2010.01.016. Epub 2010 Mar 6. Review.

32.

HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.

Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S.

Gastroenterology. 2010 Mar;138(3):905-12. doi: 10.1053/j.gastro.2009.11.013. Epub 2009 Nov 18.

33.

Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.

Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E.

Hepatology. 2009 Sep;50(3):697-706. doi: 10.1002/hep.23031.

PMID:
19582803
34.

The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?

Vanni E, Bugianesi E.

Hepatology. 2009 Jun;49(6):1790-2. doi: 10.1002/hep.23036. No abstract available.

PMID:
19475679
35.

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S.

Hepatology. 2008 Sep;48(3):792-8. doi: 10.1002/hep.22429.

PMID:
18752331
36.

NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.

Bugianesi E, Vanni E, Marchesini G.

Curr Diab Rep. 2007 Jun;7(3):175-80. Review.

PMID:
17547834
37.

Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children.

Nobili V, Marcellini M, Marchesini G, Vanni E, Manco M, Villani A, Bugianesi E.

Diabetes Care. 2007 Oct;30(10):2638-40. Epub 2007 May 29. No abstract available.

PMID:
17536073
38.

Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.

Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S.

Am J Gastroenterol. 2007 Jun;102(6):1251-8. Epub 2007 Mar 27.

PMID:
17391316
39.

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.

Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J.

Hepatology. 2006 Dec;44(6):1648-55.

PMID:
17133473
40.

Management of duodenal ulcer disease in the era of H. pylori.

Vanni E, Pellicano R, Demarchi B, Gardino L, Palmas P, Arena V, Cossotto D, Leone N, Rizzetto M, Ponzetto A, Palmas F.

Minerva Gastroenterol Dietol. 1999 Jun;45(2):89-94. English, Italian.

PMID:
16498319
41.

Diagnosis of Helicobacter pylori infection: validation of a commercial non invasive salivary test against urea breath test and serology.

Pellicano R, Vanni E, Palmas F, Astegiano M, Leone N, Fagoonee S, Ponzetto A, Rizzetto M.

Minerva Gastroenterol Dietol. 2001 Sep;47(3):111-6.

PMID:
16493368
42.

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G.

Hepatology. 2005 Aug;42(2):473-80.

PMID:
15981216
43.

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G.

Am J Gastroenterol. 2005 May;100(5):1082-90.

PMID:
15842582
44.

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.

Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G.

J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504. Epub 2005 Mar 29.

PMID:
15797948
45.

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M.

Diabetologia. 2005 Apr;48(4):634-42. Epub 2005 Mar 4.

PMID:
15747110
46.

Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?

Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G.

Dig Liver Dis. 2004 Mar;36(3):165-73. Review.

PMID:
15046183
47.

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.

Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M.

Hepatology. 2004 Jan;39(1):179-87.

PMID:
14752836
48.

Non-alcoholic steatohepatitis in patients cared in metabolic units.

Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni C, Vanni E, Manini R, Rizzetto M, Melchionda N.

Diabetes Res Clin Pract. 2004 Feb;63(2):143-51.

PMID:
14739055
49.

The future management of nephrology and dialysis.

Graziani G, Vanni E.

J Nephrol. 2003 Nov-Dec;16 Suppl 7:S30-3.

PMID:
14733298
50.

Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance.

Marchesini G, Pagotto U, Bugianesi E, De Iasio R, Manini R, Vanni E, Pasquali R, Melchionda N, Rizzetto M.

J Clin Endocrinol Metab. 2003 Dec;88(12):5674-9.

PMID:
14671152

Supplemental Content

Support Center